

Tuba N Gide

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8365293/publications.pdf>

Version: 2024-02-01

11
papers

2,037
citations

933264

10
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

4249
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â€” Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186. | 1.7 | 11 |
| 2 | Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolimmunology</i> , 2020, 9, 1659093. | 2.1 | 62 |
| 3 | Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504. | 3.2 | 355 |
| 4 | Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6. | 7.7 | 547 |
| 5 | Interâ€”and inpatient heterogeneity of indoleamine 2,3â€”dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828. | 1.6 | 16 |
| 6 | Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1â€”Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563. | 3.2 | 249 |
| 7 | Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolimmunology</i> , 2019, 8, e1537581. | 2.1 | 61 |
| 8 | CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Antiâ€”PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045. | 3.2 | 297 |
| 9 | Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270. | 3.2 | 289 |
| 10 | Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676. | 2.9 | 150 |
| 11 | Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 51-51. | 0.8 | 0 |